Verrica reports $34.3M cash; updates on VP-102 NDA and VP-315 Phase 2 trial

Verrica Pharmaceuticals Inc.

Preliminary cash and cash equivalents of $34.3M as of Dec 31, 2022, unaudited and subject to change.
NDA for VP-102 (molluscum contagiosum) resubmitted Jan 23, 2023; PDUFA goal date expected H2 2023.
New CMO partner Piramal Pharma Solutions selected; technology transfer completed Jan 2023.
VP-315 Phase 2 Part 1 (10 patients) showed favorable safety, no serious adverse events; Part 2 to start Q2 2023.
Phase 3 trial for VP-102 (external genital warts) expected to initiate H2 2024.

item 2.02 item 8.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Verrica Pharmaceuticals Inc. reported preliminary financial results for the year ended December 31, 2022.

Period: the year ended December 31, 2022
Result: preliminary results

Exact text from the filing

On February 21, 2023, Verrica Pharmaceuticals Inc. (the “ Company ”) reported that, as of December 31, 2022, it had approximately $34.3 million of cash and cash equivalents.

View on SEC.gov

39 earnings releases filed in the last 30 days. Browse all earnings releases →

Verrica Pharmaceuticals Inc. filing history →

Source: SEC EDGAR

accession 0001193125-23-042756

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.